Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Rill

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Cancer Gene Therapy|December 1, 1994
Immunomodulatory effects of human neuroblastoma cells transduced with a retroviral vector encoding interleukin-2T Leimig, N Foreman, D Rill, et al.
Experimental Hematology|August 10, 2001
Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapyG Dotti, B Savoldo, S Takahashi, et al.
Cytokines and Molecular Therapy|September 1, 1996
Transfer of marker genes into hemopoietic progenitor cellsM K Brenner, H E Heslop, D Rill, et al.
Journal of Cellular Biochemistry|June 16, 2001
Adenovirus-mediated BMP2 expression in human bone marrow stromal cellsE A Olmsted, J S Blum, D Rill, et al.
Cancer Gene Therapy|July 31, 2001
Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphomaS Takahashi, P Yotnda, R F Rousseau, et al.
Blood|January 1, 1997
A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cellsD Dilloo, D Rill, C Entwistle, et al.
Cancer|July 15, 1993
Continuous infusion of interleukin-2 in children with refractory malignanciesR C Ribeiro, D Rill, P K Roberson, et al.
Human Gene Therapy|June 28, 2001
Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenesS Takahashi, R F Rousseau, P Yotnda, et al.
Clinical Immunology (Orlando, Fla.)|February 24, 2009
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapiesB Loftus, B Newsom, M Montgomery, et al.
Human Gene Therapy|July 3, 1998
Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastomaL C Bowman, M Grossmann, D Rill, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cancer Gene Therapy|December 1, 1994
Immunomodulatory effects of human neuroblastoma cells transduced with a retroviral vector encoding interleukin-2T Leimig, N Foreman, D Rill, et al.
Experimental Hematology|August 10, 2001
Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapyG Dotti, B Savoldo, S Takahashi, et al.
Cytokines and Molecular Therapy|September 1, 1996
Transfer of marker genes into hemopoietic progenitor cellsM K Brenner, H E Heslop, D Rill, et al.
Journal of Cellular Biochemistry|June 16, 2001
Adenovirus-mediated BMP2 expression in human bone marrow stromal cellsE A Olmsted, J S Blum, D Rill, et al.
Cancer Gene Therapy|July 31, 2001
Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphomaS Takahashi, P Yotnda, R F Rousseau, et al.
Blood|January 1, 1997
A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cellsD Dilloo, D Rill, C Entwistle, et al.
Cancer|July 15, 1993
Continuous infusion of interleukin-2 in children with refractory malignanciesR C Ribeiro, D Rill, P K Roberson, et al.
Human Gene Therapy|June 28, 2001
Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenesS Takahashi, R F Rousseau, P Yotnda, et al.
Clinical Immunology (Orlando, Fla.)|February 24, 2009
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapiesB Loftus, B Newsom, M Montgomery, et al.
Human Gene Therapy|July 3, 1998
Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastomaL C Bowman, M Grossmann, D Rill, et al.
Pageof 2